Poor Geoff Birkett at AstraZeneca. First of all he has to fend of the analysts and media about the CATIE study ( http://pharmagossip.blogspot.com/2005/09/catiepsych.html ) which shows that Seroquel is no better than an older (and much cheaper) antipsychotic and will affect this blockbusters future growth.
http://today.reuters.co.uk/news/newsArticle.aspx?type=businessNews&storyID=2005-09-22T161001Z_01_MCC258173_RTRUKOC_0_UK-ASTRAZENECA-SEROQUEL.xml&archived=False
Now, just days later, he has a bomb dropped in his lap by generics giant TEVA, who want to steal the market Seroquel already has gained.
http://www.bloomberg.com/apps/news?pid=10000102&sid=aAO3O15d14OQ&refer=uk
No comments:
Post a Comment